In vitro observations of T cell responsiveness to recall antigens during tumor necrosis factor-α-blocking therapy in patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 34, Issue 11, 2007, Pages 2264-2270

  Appel, Heiner ^a   Scheer, Rebecca ^a   Haibel, Hildrun ^a   Wu, Peihua ^a   Spiller, Inge ^a   Brandt, Henning ^a   Song, In Ho ^a   Rudwaleit, Martin ^a   Thiel, Andreas ^b   Sieper, Jochen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Deutsche Rheumaforschungszentrum   (Germany)

Author keywords

Ankylosing spondylitis; Recall antigens; T cell response; Tumor necrosis factor blocking therapy

Indexed keywords

ADALIMUMAB; ANTIGEN; CD4 ANTIGEN; CYTOKINE; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HLA B27 ANTIGEN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; FLOW CYTOMETRY; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; INTERFERON PRODUCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; ENTEROTOXINS; HUMANS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPONDYLITIS, ANKYLOSING; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35948929842     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985;44:359-67.
2. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
3. Brandt J, Bollow M, Haberle J, et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology Oxford 1999;38:831-6.
4. Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 1999;26:2622-7.
5. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology Oxford 2004;43:1072-84.
6. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
7. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92.
8. Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993;177:1575-85.
9. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
10. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114.
11. Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005;141:372-80.
12. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
13. Lugering A, Lebiedz P, Koch S, Kucharzik T. Apoptosis as a therapeutic tool in IBD? Ann NY Acad Sci 2006;1072:62-77.
14. Jasmer RM, Nahid P, Hopewell PC. Clinical practise: Latent tuberculosis infection. N Engl J Med 2002;347:1860-6.
15. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002;57:804-9. Erratum in: Thorax 2003;58:188.
16. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996;178:1274-82.
17. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361:1168-73.
18. Lein AD, von Reyn CF, Ravn P, Horsburgh CR Jr, Alexander LN, Andersen P. Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol 1999;6:606-9.
19. Arend SM, Andersen P, van Meijgaarden KE, et al. Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 2000;181:1850-4. Epub 2000 May 15.
20. Thiel A, Radbruch A. Antigen-specific cytometry. Arthritis Res Ther 1999;1:25-9.
21. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997;99:1739-50.
22. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
23. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologies Register. Arthritis Rheum 2006;54:2368-76.
24. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF-alpha. Ann Rheum Dis 2001;60:750-5.
25. Zou J, Rudwaleit M, Brandt J, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003;48:780-90.
26. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
27. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.
28. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:12615.